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179* Water ﬁlters can prevent Stenotrophomonas maltophilia
contamination of nebulizer equipment used by people with
cystic ﬁbrosis (CF)
R. Woodhouse1, D. Peckham2, S. Conway2, M. Denton1. 1Microbiology, Leeds
Teaching Hospitals, Leeds, United Kingdom; 2Adult Cystic Fibrosis Unit, Seacroft
Hospital, Leeds, United Kingdom
Introduction: The epidemiology of Stenotrophomonas maltophilia in cystic ﬁbrosis
(CF) is poorly understood. Studies have shown that it may contaminate 10−15%
of nebulizer equipment. This may originate from rinsing equipment in tap water
between use. We assessed the ability of water ﬁlters to reduce contamination of
reusable nebuliser equipment rinsed in this way.
Methods: Two taps, delivering water contaminated with S. maltophilia, were
identiﬁed. One was ﬁtted with an end-line water ﬁlter (Pall-Aquasafe AQ14F1S,
Pall Medical, Portsmouth, UK) containing a sterilising grade membrane. Both were
used to rinse disposable nebulisers for up to 8 weeks and these were sampled
regularly throughout. The process was repeated using a standard inoculum (1,000
cfu/ml) of the two tap isolates and a clinical isolate obtained from CF sputum, each
delivered either unﬁltered or through water ﬁlters onto separate nebulisers. These
were sampled as above.
Results: The nebuliser rinsed in unﬁltered tap water became contaminated with
S. maltophilia after 3 weeks. All three nebulisers rinsed with the unﬁltered water
containing 1,000 cfu/ml S. maltophilia became contaminated within 7 days. All
nebulisers rinsed in ﬁltered tap water or the ﬁltered standard inoculum remained
uncontaminated after 8 weeks rinsing.
Conclusion: The use of water ﬁlters prevented S. maltophilia contamination of
nebuliser equipment for up to 8 weeks in this laboratory study. Further studies
are needed to assess the clinical impact of routine use of water ﬁlters on the
epidemiology of S. maltophilia and other water-borne pathogens in CF.
This study was part-funded by an educational grant from Pall Medical, Portsmouth,
UK.
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Achromobacter xylosoxidans has been suggested as pathogen in lung disease of
patients with cystic ﬁbrosis (CF), however, its clinical relevance is not clear yet. The
aim of this study was to assess the prevalence and importance of this agent in CF
patients seen at the outpatient pediatric CF reference center at the State University
Hospital, Unicamp, Brazil from 01/01/2005 to 12/31/2007. The microorganisms
were identiﬁed by conventional biochemical tests (Manual of Clinical Microbiology
9th ed, 2007 – ASM), the Vitek®, and for Achromobacter xylosoxidans through the
sequencing of the gene 16SrRNA. The evaluation of the antimicrobial sensitivity
was done by E-test ®. In this period of 03 years were obtained 1350 sputum and
oropharyngeal secretions samples from 216 patients, with an average of 4.5 samples
per patient. The relative frequency of isolation of Achromobacter xylosoxidans was
7.41% (16 patients in 216). Among these (16 CF patients) the prevalence was 24%
of the samples collected. The retrospective analysis of the medical records and
clinical monitoring showed that only one of them had pulmonary exacerbation at
the time of isolation of the agent. For this patient the prevalence of this agent was
53% of the samples collected. The other patients had transient colonization without
evidence of clinical signiﬁcance. These ﬁndings conﬁrm those of the literature that
shows this microorganism as an agent of chronic colonization, with eventual chronic
infection, low virulence and no clear role in the impairment of pulmonary function.
181 In vitro activity of taurolin against multiple antibiotic
resistant strains of Gram-negative non-fermenters including
Stenotrophomonas maltophilia and Achromobacter xylosoxidans
from lung transplant patients
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Kingdom
Purpose: Stenotrophomonas maltophilia and Achromobacter xylosoxidans are re-
covered from cystic ﬁbrosis patients with increasing frequency. These and other
Gram-negative non-fermenters are frequently resistant to multiple antibiotics and
may contribute to the mortality of lung transplant recipients.
Taurolin is a disinfectant which is used as a 2% solution at time of transplant
to decontaminate the thoracic cavity in patients with suppurative lung infections,
namely cystic ﬁbrosis and bronchiectatic patients. Taurolin is also administered
intravenously as salvage therapy in some circumstances.
The purpose of this study was to investigate the efﬁcacy of taurolin against a
selection of these organisms isolated from pre and post lung transplant patients.
Method: The minimum inhibitory concentration (MIC) of taurolin was determined
using the established agar dilution method. Thirty Gram-negative non-fermenters in-
cluding Stenotrophomonas maltophilia, Achromobacter xylosoxidans, Pseudomonas
ﬂuorescens, Ochrobactrum anthropi, Chryseomonas septicum, Alcaligenes denitri-
ﬁcans, Brevundimonas vesicularis and Comamonas testosteroni were examined.
Results: All strains were inhibited at a concentration of either 0.03% or 0.06%.
Conclusion: Previous studies have shown the efﬁcacy of taurolin in the inhibition
of Pseudomonas aeruginosa and Burkholderia cepacia complex. Post-operative in-
fections with multiple antibiotic resistant organisms is a challenge for the clinician.
The results of this study indicate that taurolin is an effective agent that can be used
to eradicate these organisms from the thoracic cavity.
Supported by: Microbiology Department Freeman Hospital.
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Background: Chronic airway infections caused by resistant Gram-negative micro-
organisms such as Achromobacter xylosoxidans, Burkholderia species and Ralstonia
species are an increasing problem in CF patients. Since 1992 we have occasionally
used inhaled ceftazidime, 2 g b.i.d. in these infections. This study is a report on
cases treated in 2006−7.
Patients: Patients treated with inhaled ceftazidime for at least 3 months because of
a chronic infection caused by A. xylosoxidans, B. multivorans or Ralstonia species.
Change in lung function (percent of predicted per month), days on iv antibiotics
and percentage of sputum samples positive for the relevant micro-organisms were
compared for 8 months prior to treatment and for the ﬁrst 3 months of treatment.
Results: 11 patients (5 males) were included. 9 patients were chronically infected
with A. xylosoxidans, 1 with B. multivorans and 1 with R. manitollilytica. Before
treatment, median change in FEV1 was −1.1% per month (range −3.5−0.2). This
changed to +1.4% per month (range −2.7−10) (p< 0.04). FVC changed from −0.9%
per month (range −1.9−2.5) to +1.7% per month (range −2.5−5.5) (n.s.). No
difference was found in sputum samples. Number of days on iv antibiotics per
month decreased slightly from 3.5 days/month (range 0.9−16.6) to 2.3 days/month
(range 0−9.3) (n.s.).
Conclusion: Inhaled ceftazidime might represent a new and valuable treatment of
cystic ﬁbrosis patients with chronic pulmonary infection caused by Gram-negative,
multiresistant micro-organisms. The treatment might be effective even if the micro-
organisms are relatively resistant to ceftazidime. Further investigations are needed.
